Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 09 April 2015 19:21
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience.
Read more...
 
Why Biotech Investors Should Target the Takeouts: Cantor Fitzgerald's Irina Rivkind Koffler Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 02 April 2015 14:39
Taking a page out of Big Pharma's playbook—looking for likely takeout candidates—is a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and technologies, and the resources to track those drugs and technologies down.
Read more...
 
Five Stocks Griffin Securities' Keith Markey Thinks Could Double or Triple Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 March 2015 12:50
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock.
Read more...
 
How to Beat the Herd Mentality: Highline's Michael Higgins Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 26 February 2015 15:04
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island.
Read more...
 
Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn Print E-mail
By Staff - The Life Sciences Report   
Thursday, 19 February 2015 15:38
Immuno-oncology disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it took center stage in the drug development world in 2014.
Read more...
 
Bloom Burton's David Martin Zeroes In on Under-the-Radar Biotech Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 February 2015 16:26
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and undervalued.
Read more...
 
Capture Growth with Baskets of Biotechs: LifeSci Advisors' Andrew McDonald Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 05 February 2015 19:01
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development.
Read more...
 
The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? Print E-mail
By Tracy Salcedo-Chourré of The Life Sciences Report   
Thursday, 29 January 2015 18:14
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond.
Read more...
 
What's Next for Biotech in 2015? Print E-mail
By The Life Science Report   
Thursday, 15 January 2015 08:42
Are life sciences stocks in a bubble? Will this be the year biotech overshadows big pharma?
Read more...
 
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off Print E-mail
By Sharon di Stefano   
Monday, 12 January 2015 19:19
When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and investors take notice. Few other accolades are held in such high esteem.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 56

Newsletter